Abstract:Streptococcus pneumoniae remains a leading cause of morbidity and mortality in children <5-years-old in sub-Saharan Africa. Monitoring serotype-specific nasopharyngeal colonisation can serve as a proxy to evaluate the effect of vaccination against vaccine-serotype (VT) disease. We evaluated the impact of 13-valent pneumococcal conjugate vaccine (PCV13, 2+1 schedule) immunisation on pneumococcus, and other bacterial colonisation among healthy rural South African children <60-months-old, eight years after PCV introduction. Nasopharyngeal swabs collected during two cross-sectional surveys in the Bushbuckridge sub-district, Mpumalanga from May-October 2009 (Period-1, 630) and July 2017-February 2018 (Period-2, 568) and tested for 92 pneumococcal serotypes and 15 other bacteria using high-throughput real-time PCR. Comparing Period-2 to Period-1, there was a lower overall (76.9% vs. 83.2%, adjusted Odds Ratio [aOR]:0.65, 95%CI:0.48-0.87) and PCV13-VT colonisation prevalence (14.3% vs. 51.0%; aOR:0.16, 95%CI:0.12-0.21). In Period-2 VT 19F (5.3%) and 6B (4.8%) dominated, albeit at a lower prevalence compared with Period-1 (10.3%, aOR:0.52, 95%CI:0.33-0.82 and 15.2%, aOR:0.26, 95%CI:0.16-0.41, respectively). Non-vaccine-serotype (NVT) colonisation was higher in Period-2 (63.2%) than Period-1 (35.6%, aOR:3.12, 95%CI:2.45-3.97), driven by 16F (8.1% vs. 0.3%) and 23B (5.1% vs. 3.5%). Non-typeable pneumococci were higher in Period-2 (21.8%) compared with Period-1 (12.5%, aOR:1.94, 95%CI:1.42-2.67). Other differences included a higher prevalence in Period-2 of Acinetobacter baumannii (36.8% vs 1.1%, aOR:50.11, 95%CI:23.14-108.50), Klebsiella pneumoniae (13.2% vs 0.6%, aOR:22.16, 95%CI:8.03-61.11), Streptococcus pyogenes (2.5% vs 0.2%, aOR:14.49, 95%CI:1.89-111.09) and Neisseria lactamica (8.1% vs 4%, aOR:2.14, 95%CI:1.28-3.57), whereas Streptococcus oralis (0.5% vs 2.2%, aOR:0.21, 95%CI:0.06-0.77) and Moraxella catarrhalis (60.4% vs 67.8%, aOR:0.72, 95%CI:0.56-0.91) were lower. There was an 80% lower prevalence of PCV13-VT serotype colonisation after eight years of routine PCV immunisation, however, there was high residual prevalence of 19F and 6B, serotypes that also persist in disease. The clinical relevance of temporal changes in colonization by other bacteria warrant further investigation.

Nasopharyngeal Pneumococcal Colonization and Impact of a Single Dose of 13-Valent Pneumococcal Conjugate Vaccine in Indian Children With HIV and Their Unvaccinated Parents

Streptococcus pneumoniae Acquisition and Carriage in Vaccine Naïve Indian Children with HIV and their Parents: A Longitudinal Household Study

Nasopharyngeal colonization by Streptococcus pneumoniae and other common bacteria eight years following introduction of pneumococcal conjugate vaccine in rural South African children ≤5 years old.

Impact of 13-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Carriage Rates of Streptococcus pneumoniae in a Rural Community in the Dominican Republic

Nasopharyngeal carriage of Streptococcus pneumoniae among children <5 years of age in Indonesia prior to pneumococcal conjugate vaccine introduction

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India

Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial

Pneumococcal population genomics changes during the early time period of conjugate vaccine uptake in southern India

Pneumococcal Conjugate Vaccine Impact on Meningitis and Pneumonia Among Children Aged <5 Years-Zimbabwe, 2010-2016

Incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate pneumococcal vaccine in British Columbia: A retrospective cohort study

Radiographically confirmed pneumonia in Malawian children and associated pneumococcal carriage after introduction of the 13-valent pneumococcal conjugate vaccine

Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Community Acquired Pneumonia among Children in China, an Observational Cohort Study

High residual carriage of vaccine-serotype Streptococcus pneumoniae after introduction of pneumococcal conjugate vaccine in Malawi

Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults

Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States

Long-term impact of 10-valent pneumococcal conjugate vaccine in Kenya: Nasopharyngeal carriage among children in a rural and an urban site six years after introduction

Determining the pneumococcal conjugate vaccine coverage required for indirect protection against vaccine-type pneumococcal carriage in low and middle-income countries: a protocol for a prospective observational study

Effects of Probiotic Mixture Supplementation on the Immune Response to the 13-Valent Pneumococcal Conjugate Vaccine in People Living with HIV

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis